Conference Coverage

Normal-weight prediabetes patients also benefit from lifestyle intervention


 

FROM ADA 2020

Key findings

With a mean follow-up of 145 days, weight loss in the obese group was greater than that of the overweight group, with mean BMI changes of –1.3 and –0.6, respectively, while there was no significant change in weight for the normal-weight individuals, according to Ms. Salmon.

By contrast, weekly aerobic activity increased significantly in all three groups, she added, with average increases of 95 minutes in the obese group, 98 minutes in the overweight group, and 77 minutes in the normal-weight group.

Likewise, significant decreases in FPG were seen in all 3 groups, with average changes of –6 mg/dL for the obese participants, –7 mg/dL for overweight participants, and –9 mg/dL for normal-weight participants, Ms. Salmon said.

The proportion of individuals whose FPG normalized was highest in the normal-weight group, at 62%, compared with 51.7% for overweight and 44% for obese individuals, she added.

Most previous studies of lifestyle interventions for prediabetes have excluded normal-weight individuals, according to Ms. Salmon, who said one strength of her study was that the subjects were already participating in the established lifestyle health coaching program and didn’t interact with the team of researchers.

“It was an effectiveness study in which we could see the real-world benefits of the program, rather than a theoretical efficacy study,” she said.

Ms. Salmon said she had no potential conflicts of interest to disclose. The coinvestigators of the study were members or employees of a privately held population health management company called INTERVENT International.

SOURCE: Salmon MK et al. ADA 2020, Abstract 273-OR.

Pages

Recommended Reading

VERTIS-CV: Ertugliflozin’s CV outcomes trial confirms SGLT2i benefits
MDedge Endocrinology
Dapagliflozin’s T2D renal protection extends to ‘fast decline’ of eGFR
MDedge Endocrinology
Where does dexamethasone fit in with diabetic ketoacidosis in COVID-19?
MDedge Endocrinology
Lyumjev ultra-rapid-acting insulin gets FDA nod  
MDedge Endocrinology
Lipid-lowering bempedoic acid does not hasten or worsen diabetes
MDedge Endocrinology
Daily Recap: Headache as COVID evolution predictor; psoriasis drug treats canker sores
MDedge Endocrinology
Cost of preventable adult hospital stays topped $33 billion in 2017
MDedge Endocrinology
FDA approves metoclopramide nasal spray for diabetic gastroparesis
MDedge Endocrinology
T2D plus heart failure packs a deadly punch
MDedge Endocrinology
ED visits for life-threatening conditions declined early in COVID-19 pandemic
MDedge Endocrinology